Human immunodeficiency virus (HIV) types 1 and 2 are the etiologic agents of AIDS in humans. The generation of a prophylactic HIV vaccine to prevent infection or HIV-induced disease is a major objective in the control of the HIV epidemic. Primate animal models useful for HIV vaccine studies have been established, including infection of chimpanzees with HIV-1 and infection of macaques with HIV-2, the closely related simian immunodeficiency viruses (SIVmac, SIV sm , SIVmne), or chimeric SIV/HIV-l [1, 2] . SIV causes an AIDS-like disease in macaques, whereas HIV-1 infection of chimpanzees and HIV-2 infection of cynomolgus or rhesus macaques are not associated with disease, at least not during 2 years of followup. Although results have been promising in some of the experimental models, several problems still need to be solved before an applicable vaccine formula can be introduced for wider use in humans. A major obstacle is the lack of information on the more precise mechanisms involved in a protective immune response against HlV infection. Cellular immune responses have been shown to have an important role in clearing viral infections in experimental systems using influenza virus [3] and murine leukemia virus [4, 5] . Significant cellular and humoral immune reactions have been detected in HlV-infected persons and in HIV-2-and SIVinfected macaques, but the relative importance of these immune reactions in the defense against HlV and SIV infections has not been established [6] [7] [8] .
HIV-2 infection of cynomolgus monkeys is a relevant animal model for testing vaccine-induced protection against infection. We previously demonstrated that immunization with whole inactivated HTV-2 [9, 10] or an HIV-2 gp125 subunit preparation [11] completely prevented infection with homologous HIV-2 in some vaccinated cynomolgus monkeys. Passive immunization of naive monkeys with serum from an HIV-2-vaccinated and protected monkey conferred protection against infection [12] . Furthermore, by immunizing cynomolgus monkeys with a live attenuated HIV-2 vaccine, cross-protection was elicited against SIVsm-induced immunodeficiency and disease even though the SIV infection was not prevented [13, 14] .
There is evidence from other primate studies that various HIV or SIV prime-boost protocols can protect against homologous virus challenge. In chimpanzees, protection against cellfree or cell-associated HIV-1 was obtained with an immunization schedule including whole inactivated virus or purified recombinant proteins followed by HIV-1 V3 synthetic peptides [15, 16] . Pig-tailed macaques immunized with recombinant vaccinia virus expressing SIVmne gp 160 and boosted with a subunit gp 160 were protected against challenge with homologous cloned virus [17] .
Live recombinant virus vectors, such as recombinant poxviruses expressing various inserted immunogens, provide a means of mimicking viral infection and eliciting both humoral and cell-mediated immunity. The recombinant canarypox viruses have the advantage of being restricted for productive replication to avian species. When inoculated into nonavian species, the extrinsic immunogens are expressed, without further production of canarypox virus [18 -21] . Canarypox virus vectors called ALVAC expressing feline leukemia virus (Fe LV) proteins have been shown to elicit protection against persistent viremia on live mucosal FeLV challenge in cats [19] . In cats and dogs, protective immune reactivity against rabies has been obtained after recombinant canarypox or vacciniarabies immunizations [20] . Protection against human T cell lymphotropic virus type I (HTLV-I) was conferred in some rabbits immunized with HTL V-I Env recombinant canarypox or vaccinia virus [22] . In humans, immunization with canarypox virus expressing rabies glycoprotein or the HIV -1 envelope glycoprotein has been safe and immunogenic [23, 24] .
The work presented here includes two sets of experiments using HIV -2 recombinant canarypox virus (ALVAC HIV -2) vaccine candidates in cynomolgus monkeys. In the first experiment, we studied the immunogenicity and efficacy of an AL-VAC HIV-2 vaccine candidate given alone or followed by an envelope gp 125 subunit preparation during a total immunization period of 7 months. In the second experiment, a longer immunization schedule was used, and V3 peptides were included for booster injections in 1 group. Humoral and cellular immune responses were studied in relation to immunization schedules and outcome after live virus challenge.
Materials and Methods
Immunogens. Recombinant canarypox viruses containing HIV-2 gene products were generated essentially as described elsewhere [18] [19] [20] [21] . Two different ALVAC constructs were used for immunizations: vCP188, expressing the entire HIV-2 Env gene product, and vCP206, expressing the HIV-2 gag and pol gene products and a form of the HIV-2 Env gene product, gpI20(TM), from which the entire gp41 coding sequence, except for the 28 codons encoding the transmembrane region, have been deleted. Native HIV-2 Env gp125, purified by affinity chromatography using Galanthus nivalis agglutinin [25] or synthetic peptides corresponding to the V3 region of the HIV-2 envelope were used for booster immunizations. Two synthetic peptides were used, A 32-11, corresponding to aa 311-326 (sequence SGRRFHSQKI-INKKPR[C]), and 32-13, corresponding to aa 322-337 (NKKPRQAWCRFKGEWR[C]) [26] . The booster immunizations were given intramuscularly (im) in a saponin adjuvant (QS21) derived from the soapbark tree (Quillaja saponaria) [27] .
Animals, immunization schedule, and viral challenge. Twentysix cynomolgus monkeys (Macacafascicularis) of both sexes and of various ages were either vaccinated (n = 14) or used as controls (n = 12). Two separate experiments were done.
The first experiment included 3 groups of animals. In group A, 4 monkeys (B181, B182, B185, and B186) were given 10 7 pfu im of ALVAC (vCP206) expressing the HIV-2 gp120(TM) and gag and pol gene products at 0, 1, and 7 months. In group B, 4 monkeys (Bl75, B176, B179, and B180) were immunized with 10 7 pfu im of ALVAC (vCP206) expressing the HIV-2 gpI20(TM) and gag and pol gene products at 0 and 1 months, followed by 60 f.1g im of purified native HIV-2sBL-6669 gp125 in QS2l at 7 months. In group C, consisting of 8 control monkeys, 4 (B187-B190) were given parenteral ALVAC only, and 4 (nos. 69-72) were not treated. One month after the last immunization, the vaccinated monkeys and the controls were challenged intravenously (iv) with 30 MID so (50% monkey infectious dose) of homologous HIV-2 sBL_ 6669 grown in monkey peripheral blood mononuclear cells (PBMC).
The second experiment also consisted of 3 groups of animals. In group D, 3 monkeys (BI95, B196, and C5) received 10 7 pfu im of ALVAC (vCP188) expressing HIV-2 env at 0 and 1 months, followed by HIV~2 gp125 in QS21 adjuvant at 7 and 12 months. Finally, at 14 months they received 10 7 pfu im of ALVAC (vCPI88) HIV-2 env again. In group E, 3 monkeys (C3, C7, and C8) were given 10 7 pfu im of ALVAC (vCPI88) HIV-2 env at 0, 1, and 7 months, followed by HIV~2 V3 peptides (50 f.1g im) in QS21 at 10 and 12 months and a final booster immunization with 10 7 pfu im of ALVAC (vCPI88) HIV-2 envat 14 months. In group F, 4 control monkeys (BI91, B192, C9, and CI0) received parenteral ALVAC only at 0, 1, 7, and 14 months. These monkeys were challenged iv with 30 MID so of homologous HIV-2sBL-6669 2 weeks after the last immunization.
Serologic assays. Serum levels of HIV-2-specific antibodies were determined by ELlSAs using HIV-2SBL-6669 whole virus lysate [28] , purifiednative envelope gp125, orV3 peptide [11] .Neutralizing antibodies were determined using PBMC as target cells, as previously described [10] ; the virus used in these assays had been grown in human PBMC.
Assay for cytotoxic T lymphocytes (eTL). Autologous B 1ymphoblastoid cell lines (BCL) were used as target cells in the CTL assays. The BCL were generated from fresh monkey PBMC isolated by Ficoll-Paque gradient (Pharmacia, Uppsala, Sweden) from venous blood drawn into Vacutainer tubes (Becton Dickinson, Mountain View, CA) containing EOTA. Cells were cultured in flat-bottomed 96-well microtiter plates with 2 X lOS/well, in 100 f.1L of complete RPMI (i.e., with glutamine, penicillin/streptomycin, and 10% fetal calf serum [FCS] ). B cells were transformed by infection with herpes papio virus produced in the S594 cell line (provided by K. H. G. Mills, National Institute for Biological Standards and Control, Potters Bar, Hertfordshire, UK). To each well containing PBMC, 100 j.tLof supernatant from S594 cultures was added, giving a total volume of 200 j.tL (l0 6 cells/mL). Transformation usually occurred within 3-4 weeks of culture. Despite several attempts, BCL could not be established from monkeys B175 and B182.
Effector cells were generated from fresh Ficoll-Paque-purified monkey PBMe. The cells were cultured in complete RPMI and stimulated with 10 j.tg/mL concanavalin A (conA; Sigma, St. UK) for at least 10 and not more than 24 days before being assayed. Effector cells were washed once and put in a final concentration of 5 X 10 6 cells/mL in assay medium (i.e., complete RPMI containing 20 mM HEPES; Life Technologies, Paisley, UK).
The HIV-2-specific CTL were assayed in a standard chromium release assay. Target cells were infected 24 h prior to assay with attenuated recombinant vaccinia virus (rVV) constructs (NYV AC) [29] containing HIV-2 gag and pol (vP1045) and env genes (vP920) or the parental vaccinia virus alone (vP866). Infection was established in 0.75-1 X 10 6 cells in RPMI with 2% FCS, penicillin/streptomycin, and glutamine and incubated with 5 pfu/ cell of the various rVV in separate tubes for 1 h. The cells were then washed three times in RPMI and kept overnight in complete RPM!. On the day of assay, the cells were washed once and then labeled with 200 /-lei/antigen of 51Cr (DuPont, Wilmington, DE) for 2 h. The cells were washed three times and placed in assay medium at a final concentration of 5 X 10 4 cells/mL.
An effector-to-target cell ratio of 100: 1 was usually used. Thus, 5 X 10 5 and 5 X 10 3 cells/well, respectively, of effector and target cells were mixed and incubated in 200 /-lL of assay medium in triplicate in round-bottomed 96-well microtiter plates for 4 h in 37°C, 5% CO 2 • The plates were then centrifuged at 200 g for 5 min, and the supernatants were transferred to ,B-plate filtermats. The concentration of 51Cr in the supernatants was analyzed on a 1205 ,B-plate scintillation counter (Wallac, Turku, Finland). Control wells included target cells in medium only for analysis of spontaneous lysis and target cells plus 5% Triton X-I 00 for maximum release of 51Cr. Percent specific lysis was calculated according to the formula: counts per min (cpm) (experimental) -cpm (spontaneous)/cpm (maximum) -cpm (spontaneous) X 100. A run was considered valid if the spontaneous lysis of target cells in medium was not > 30% of the maximum lysis.
The criteria for a positive CTL value were based on the results obtained in nonimmunized noninfected control monkeys. The mean of all control results (n = 51) for HIV -2 Gag and Pol (Gag/ Pol) and Env antigens, respectively, plus 2 SD was considered positive. However, the trend in each animal was always considered, and a single positive value was never accepted unless confirmed on another occasion. CD4 or CD8 T lymphocytes were removed with Dynabeads M450 (Dynal, Skeyen, Norway) according to manufacturer's instructions. HLA restriction of the CTL response was controlled with a mismatch of target and effector cells (i.e., nonautologous target cells were used).
Lymphocyte proliferation assay. Lymphocyte proliferation was assayed using Ficoll-Paque-purified monkey PBMC in triplicate (2 X 105 cells/well) in 96-well flat-bottomed microtiter plates (Nunc, Roskilde, Denmark) in a final volume of 200 /-lL of RPMI 1640 with 10% AB-positive serum, L-glutamine, and penicillin/ streptomycin (Life Technologies). The cells were stimulated with phytohemagglutinin (PHA; Difco, Detroit) (positive control), HIV-2SBL-6669 whole virus antigen prepared as previously described [30] , purified native HIV-2 gpl25 [25] , or HIV-2 V3 peptide A32-11 (26] or cultured in medium only (negative control). The cultures were kept for 2 (PHA) and 4 days (specific antigens) at 37°C, 5% CO 2 , Then O.l /-lCi/well [3H]thymidine (Amersham) was added, and the cells were cultured for another 24 h at 37°C, 5% CO 2 . The cultures were harvested with a cell harvester (Skatron, Lien, Norway), and radioactive uptake in the cells was measured on a 1205 ,B-plate counter. Stimulation index (SI) was calculated according to the following formula: cpm (mean of triplicate measurements)/cpm (mean of unstimulated control cells).
Virus isolation and polymerase chain reaction (peR). Virus from monkey PBMC was isolated by cocultivation of PHA-stimulated uninfected human PBMC, as previously described [11] . HIV-2 gag, pol, env, and long terminal repeat proviral sequences in monkey PBMC were detected by nested PCR, as described elsewhere [31] .
Results

Safety.
No adverse reactions or lesions due to the injections of the various immunogens were noted. The CD4 T lymphocyte levels were normal and stable throughout the course of immunizations.
Antibody responses. Antibody titers to HIV-2 gpI25 demonstrated by ELISA were generally higher in the monkeys that received one or two booster immunizations with gpI25 (group B) compared with the monkeys immunized with AL VAC HIV-2 only (group A) and the monkeys boosted with V3 peptides (group E) (figure 1). The antibody titers to V3 were generally low in all groups, ranging from < 1120 to 11500 except for that of B 180, which had a titer of 112500 (table 1). Low antibody titers (::;::; 1/ 100) to whole HIV -2SBL-6669 were observed before challenge in all groups except D (given ALVAC HIV -2 env with gp125 boost), in which 2 animals had titers of 112500 and 11500 (table 1) . At challenge, the titers of neutralizing antibodies were low (::;::;20) in all but 2 immunized monkeys (table 1). All animals had an increased antibody response to HIV-2 viral lysate following challenge (data not shown). An increased antibody response to purified gpl25 was demonstrated in all animals except monkeys C8 (group E) and C5 (group D) (figure 1) after live HIV-2 exposure.
Lymphocyte proliferative responses. The highest SIs in response to killed HIV -2 virions were noted in the 4 monkeys immunized with the ALVAC HIV-2 gp 120(TM) and gag and pol gene products followed by gp 125 (group B) and in 1 of the monkeys (B 196) in group D immunized with AL VAC HIV -2 env and gp 125 (table 1) . Most of the other animals also had higher SIs than did controls. The SIs after stimulation of cultures with purified gp 125 were generally low, although slightly elevated over that of the control groups. Of 3 animals in each of groups D and E, 1 in each group had an increased SI after V3 peptide stimulation (table 1) . The SI in response to killed HIV -2 virions increased after challenge in 3 of 4 monkeys in group A (data not shown). The control animals had low SIs throughout the study.
CTL. The means of 51 control values for naive control monkeys in the HIV -2 CTL experiments were 1.5% (SD, 1.6) lysis for Gag/Pol and 2.9% (SO 2.9) for Env. Thus, the approximate lower limits for a positive CTL were 4.7% (1.5 + 2SD) for Gag/Pol and 8.7% (2.9 + 2SD) for Env. ELISA antibody titers to gp 125 in immunized monkeys. Group A was immunized 3 times with ALVAC vCP206, expressing HIV-2 gp 120(TM) and gag and pol gene products. Group B was given ALVAC HIV-2 gp120(TM) gag and pol 2 times followed by purified native HIV-2sBL_6669 gp125 1 time. Group D received ALVAC HIV-2 env 2 times, gp125 2 times, and finally, ALVAC HIV-2 env 1 time. Group E was given ALVAC HIV-2 env 3 times, HIV-2 V3 peptides 2 times, and finally, ALVAC HIV-2 env 1 time. Antibody titers were measured 2 weeks after each immunization (indicated by roman numerals), at challenge, and 4 and 8 weeks after challenge. Time scale is not proportionaL Viral challenge is indicated by arrow.
immunizations, prior to challenge (tables 2, 3). CTL responses after challenge were increased in a majority of monkeys, including the controls. The exceptions were 2 of 3 monkeys in group D and 1 of 3 in group E, in which no significant CTL response was noted either before or after challenge (tables 2, 3). HLA restriction of the CTL response was shown in B 181, where a mismatch of effector and target cells obliterated the CTL response. After removal of CD8 cells, no CTL response was detected in animals otherwise having high levels of HIV-specific CTL (data not shown).
Outcome of HIV-2 challenge.
The results of virus isolation and PCR after challenge with HIV-2 are shown in table 4. None of the 4 monkeys immunized with the ALVAC HIV-2 gpI20(TM) and gag and pol vaccine only (group A) showed evidence of protection against HIV-2 infection. Virus was isolated from their PBMC, and they were positive by PCR for HIV-2 DNA. In contrast, 2 of 4 monkeys immunized twice with ALVAC HIV-2 gpI20(TM) and gag and pol (vCP206) vaccine and once with HIV-2 gp 125 (group B) were repeatedly negative on virus isolation and PCR after challenge with HIV-2. Virus isolation and PCR were also negative in I of 3 monkeys in group D immunized with ALVAC HIV-2 env and HIV-2 gp125 and in I of the 3 monkeys in group E immunized with ALVAC HIV-2 env and V3 peptides. All 12 challenged control macaques became infected; all seroconverted, and their PBMC were positive for viral DNA by PCR. Virus was repeatedly isolatedfrom all but 1 monkey. In the vaccinated monkeys, no correlation was observed betweenthe humoral and cellular responses prior to challenge and protection against infection.
Discussion
In this study, protection against challenge with homologous HIV -2 was achieved in 4 of 10 monkeys immunized with ALVAC HIV-2 followed by purified HIV-2 gpl25 or V3 synthetic peptides. In contrast, none of 4 monkeys given ALVAC HIV-2 alone was protected. The 4 protected monkeys had no detectable virus when their PBMC were tested repeatedly by virus isolation and PCR. Nevertheless, they showed an increase in the titer of virus-specific antibodies against whole virus antigen after challenge, suggesting that transient, limited viral replication occurred. In a previous experiment, in which monkeys were immunized with live HIV -2 and challenged with SIVsm-we found that the HIV-2 vaccine prevented the development of Sl V-induced disease without preventing SIV infection, indicating that complete sterilizing immunity is not a prerequisite for protection against AIDS [14] . It should be noted that the protection achieved in the monkeys in the present study cannot be attributed to human xenoantigens, as was the case in some studies of inactivated whole SIV vaccines [32] , since our challenge virus was propagated in monkey PBMC.
In the first set of experiments in the present study, protection against HIV-2 replication was induced in 2 of 4 monkeys immunized with ALVAC HIV-2 followed by HIV-2 gp125. In an attempt to improve vaccination efficacy, we increased the number of immunizations and the immunization time in the second set of experiments. However, the prolonged immunization schedule did not increase the proportion of protected animals. In a recent vaccine trial in rhesus monkeys, protection against homologous HIV -2 was demonstrated in 2 of 2 monkeys immunized with ALVAC HIV-2 followed by HIV-2 recombinant envelope subunits and in 5 of 6 monkeys immunized with HIV-2 recombinant vaccinia virus (NYVAC HIV-2) in combination with recombinant envelope subunits [33] . There may be several explanations for the higher degree of protection in that study compared with those of the present study (4/ 10 monkeys protected) since the vaccine preparations, the immuni- Table 2 . HIV-2-specific cytotoxic T cell responses (% specific lysis) in monkeys immunized with AL V AC HIV-2 only (group A) or ALV AC HIV-2 followed by gp 125 (group B) and challenged with HIV-2 (both groups). zation schedule, and the macaque species were different. In another study, cross-protection against HlV-2 challenge was demonstrated in 3 of 8 rhesus monkeys immunized with ALVAC or NYVAC HIV-l vaccines followed by HIV-I subunits [34] . In humans, a phase one clinical trial using ALVAC HIV-1 gp160 in combination with recombinant gp160 showed that the vaccine was safe and that it induced both humoral and cell-mediated immune responses [24] . HIV-l-specific CTL responses were also demonstrated in another study of humans immunized with ALVAC HIV-l gpl60 [35] .
In the present and in previous HIV-2 or SlV vaccine trials in macaques, no correlation was found between any of the immunologic parameters studied and protection [2, 10, 11, 33, 36] . The neutralizing antibody titers to HIV-2 grown in human PBMC were generally low in the immunized monkeys in the present study. We previously showed that the neutralizing ac- Table 3 . HIV-2-specific cytotoxic T lymphocyte (CTL) responses (% specific lysis) in monkeys immunized with ALVAC HIV-2 env followed by HIV-2 gp125 (group D) or ALVAC HIV-2 env followed by V3 peptides (group E) and challenged with HIV-2 (both groups). tivity is lower against virus grown in PBMC than against virus grown in human cell lines [10] . In the present study, the 2 animals with the highest levels of neutralizing antibodies were not protected. Similarly, a high ELISA antibody titer, whether to purified gpI25, V3 peptides, or whole HIV-2 virions, was not predictive of protective immunity. Nor was there any correlation between the presence of HIV-2-specific CTL response and protection. None of the protected monkeys had significant CTL levels before or at the time of challenge, whereas 3 nonprotected monkeys had demonstrable CTL prior to challenge. Lymphocyte proliferative responses to HIV-2 virions or gpl25 were demonstrated in most immunized animals, but there was no correlation between the level of the SI and protection. The finding of a lymphocyte proliferative response to V3 peptides in 2 protected monkeys but in none of 4 nonprotected monkeys might be fortuitous. The nature of the protective mechanisms needs to be further characterized to make it possible to establish indicators of protection and to improve our understanding of how to design and administer proper vaccines for HIV.
It seems reasonable to assume that a combination of humoral and cellular immune factors is involved in protection against HIV infection. Neutralizing antibodies may playa role in the clearance of cell-free viremia. The successful transfer of protective immunity against HIV-1 infection by passive immunization of chimpanzees [37, 38] and of macaques against HIV-2 [12] indicates that antibodies are of importance for protection against HIV infection. The control of virus-infected cells should require cellular immune responses. A broad spectrum of CTL recognition, including major structural and regulatory proteins, has been observed both in HIV-I-infected humans [7] and SIV ma c -and HIV-2-infected macaques [6] . Apart from a recent study in cynomolgus macaques in which suppression of SIV replication by Nef-specific CTL was observed [39] , SIV-or HIV-2-specific CTL responses detected prior to challenge in immunized monkeys have not correlated with protec-lID 1996; 174 (November) tive immunity [2, 6, 33] . HIV-l e infected persons with no signs of disease progression despite 12-15 years of infection have been shown to exhibit a strong neutralizing antibody response and a virus-inhibitory CD8 lymphocyte response [40] .
It may be argued that a CTL assay such as ours, based on conA stimulation of bulk lymphocytes, is not optimal for detection of CTL precursors in immunized animals. The SIV vaccine-induced Nef-specific CTL reported by Gallimore et a1. [39J was detected after antigen-specific stimulation. However, the fact remains that in the present study the 3 immunized monkeys with demonstrable CTL before challenge were not protected against HIV-2 infection.
Future studies should emphasize potentially more sensitive methods for detection of cellular immune responses in immunized monkeys, such as CTL with antigen-specific stimulation. It may also be relevant to include a more detailed analysis of CTL epitopes and precursor frequencies. Furthermore, studies of immune mechanisms not assessed in our system, such as noncytolytic CD8 T cell anti-HIV responses [41) and antibodydependent cellular cytotoxicity, could provide useful information.
In conclusion, this study shows that prime-boost immunization schedules that include HIV-2 recombinant avipox vaccines can induce protective immunity in cynomolgus monkeys. It would be of interest to evaluate this immunization approach in a pathogenic system. Further research is needed to identify parameters that correlate with protective immunity.
